Antibody-Mediated Neutralization of Authentic SARS-CoV-2 B.1.617 Variants Harboring L452R and T478K/E484Q
The capacity of convalescent and vaccine-elicited sera and monoclonal antibodies (mAb) to neutralize SARS-CoV-2 variants is currently of high relevance to assess the protection against infections. We performed a cell culture-based neutralization assay focusing on authentic SARS-CoV-2 variants B.1.61...
Main Authors: | Alexander Wilhelm, Tuna Toptan, Christiane Pallas, Timo Wolf, Udo Goetsch, Rene Gottschalk, Maria J. G. T. Vehreschild, Sandra Ciesek, Marek Widera |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-08-01
|
Series: | Viruses |
Subjects: | |
Online Access: | https://www.mdpi.com/1999-4915/13/9/1693 |
Similar Items
-
Optimization and validation of RT-LAMP assay for diagnosis of SARS-CoV2 including the globally dominant Delta variant
by: Vijay Lakshmi Jamwal, et al.
Published: (2021-08-01) -
SARS-CoV-2 Delta Variant Pathogenesis and Host Response in Syrian Hamsters
by: Sreelekshmy Mohandas, et al.
Published: (2021-09-01) -
Monoclonal Antibody Therapy in a Vaccine Breakthrough SARS-CoV-2 Hospitalized Delta (B.1.617.2) Variant Case
by: Bradley A Connor, et al.
Published: (2021-09-01) -
Watching Brief: The evolution and impact of COVID-19 variants B.1.1.7, B.1.351, P.1 and B.1.617
by: Hermione Williams, et al.
Published: (2021-05-01) -
In Vitro Rapid Antigen Test Performance with the SARS-CoV-2 Variants of Concern B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), and B.1.617.2 (Delta)
by: Sabrina Jungnick, et al.
Published: (2021-09-01)